Enlivex Reports $1.2B Net Income Driven by Digital Asset Gains; Advances Allocetra™ to Phase IIb & Authorizes $20M Buyback

summarizeSummary

Enlivex Ltd. reported a significant net income of $1.236 billion for fiscal year 2025, primarily due to unrealized gains from its digital asset treasury. The company also announced FDA clearance for its Allocetra™ Phase IIb trial in osteoarthritis and authorized a $20 million share repurchase program.

check_boxKey Events

• Massive Net Income Driven by Digital Assets

  Reported $1.236 billion net income for fiscal year 2025, a significant turnaround from a $15 million net loss in 2024, primarily due to $1.631 billion in unrealized gains from its RAIN digital asset treasury and related purchase options.

• FDA Clearance for Phase IIb Trial

  Received FDA Investigational New Drug (IND) clearance in March 2026 for its Allocetra™ Phase IIb trial in age-related primary knee osteoarthritis, marking a key clinical advancement.

• $20 Million Share Repurchase Program Authorized

  The Board of Directors authorized a share repurchase program for up to $20 million of outstanding ordinary shares in March 2026, signaling confidence and potential capital return to shareholders.

• $21 Million Convertible Note Financing Secured

  Secured $21 million through a senior secured convertible promissory note in March 2026, with an initial conversion price at a premium to the current share price, providing additional working capital.

auto_awesomeAnalysis

Enlivex Ltd.'s annual 20-F filing reveals a dramatic financial shift for fiscal year 2025, reporting a net income of $1.236 billion, a substantial improvement from a $15 million net loss in 2024. This significant turnaround was primarily driven by $1.631 billion in unrealized gains from the company's digital asset treasury, which is anchored in the highly volatile RAIN prediction markets token. While the core clinical operations continue to incur losses, the company achieved a key milestone with FDA Investigational New Drug (IND) clearance for its Allocetra™ Phase IIb trial in osteoarthritis. Further bolstering its financial position and shareholder value, Enlivex secured $21 million through a senior secured convertible note at a premium to its current share price and authorized a $20 million share repurchase program. These capital management actions, alongside the clinical progress, provide a more stable outlook despite the inherent volatility of its digital asset strategy. The filing also details the extension of the RAIN Option to December 2027 and the voluntary delisting from the TASE to consolidate trading on Nasdaq.